-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Opinion|Videos|April 4, 2025

Payer and Reimbursement Considerations for Bispecific Therapies

Experts discuss how payer and reimbursement considerations affect access to bispecific therapies in different practice settings.

Video content above is prompted by the following:

How do payer and reimbursement considerations affect access to bispecific therapies in different practice settings?


Related to this article

Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.